| 8.205 0.295 (3.73%) | 11-11 15:54 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.85 | 1-year : | 11.51 |
| Resists | First : | 8.43 | Second : | 9.85 |
| Pivot price | 7.66 |
|||
| Supports | First : | 7.17 | Second : | 6.38 |
| MAs | MA(5) : | 7.79 |
MA(20) : | 7.59 |
| MA(100) : | 5.74 |
MA(250) : | 5.23  |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 65.5 |
D(3) : | 58.7 |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 10 | Low : | 2.53 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CRVS ] has closed below upper band by 7.4%. Bollinger Bands are 4.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.16 - 8.21 | 8.21 - 8.26 |
| Low: | 7.38 - 7.44 | 7.44 - 7.48 |
| Close: | 7.83 - 7.92 | 7.92 - 8 |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Sun, 09 Nov 2025
Corvus Pharmaceuticals: Moving Slowly Forward (NASDAQ:CRVS) - Seeking Alpha
Thu, 06 Nov 2025
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2025 Earnings Call Transcript - Insider Monkey
Wed, 05 Nov 2025
Corvus: Q3 Earnings Snapshot - theheraldreview.com
Tue, 04 Nov 2025
Corvus: Q3 Earnings Snapshot - Connecticut Post
Mon, 03 Nov 2025
Corvus Pharma (NASDAQ: CRVS) to present soquelitinib 1/1b T‑cell lymphoma data at ASH - Stock Titan
Sat, 01 Nov 2025
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 75 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 56.3 (%) |
| Shares Short | 8,830 (K) |
| Shares Short P.Month | 9,670 (K) |
| EPS | -1.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.9 % |
| Return on Equity (ttm) | -68.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -7.39 |
| PEG Ratio | 0 |
| Price to Book value | 7.52 |
| Price to Sales | 0 |
| Price to Cash Flow | -21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|